Publications by authors named "P W Hanlon"
Background: Frailty is of increasing interest in trials, either as a target of intervention, as an outcome or as a potential treatment modifier. However, frailty measurement is often highly variable. This scoping review assessed how frailty is quantified in randomised controlled trials (RCTs), in what context and for what purposes.
View Article and Find Full Text PDFBackground: Treatment inertia, non-adherence and non-persistence to medical treatment contribute to poor blood pressure (BP) control worldwide. Fixed dose combination (FDC) antihypertensive medicines simplify prescribing patterns and improve adherence. The aim of this study was to identify factors associated with prescribing FDC antihypertensive medicines and to understand if these factors differ among doctors worldwide.
View Article and Find Full Text PDFFrameworks have been developed to standardize the assessment of carcinogenic potential in the pharmaceutical and agrochemical industries, building upon decades of research. Carcinogenicity is also evaluated during the safety evaluation of food substances, using a comprehensive approach unique to each substance. To better understand these approaches, a retrospective assessment was conducted on the publicly available database of substances notified to the United States Food and Drug Administration (US FDA) as being Generally Recognized As Safe (GRAS).
View Article and Find Full Text PDFArticle Synopsis
- - This study seeks to better classify individuals with multiple long-term health conditions (MLTCs) by identifying specific clusters of these conditions across various age groups and their links to negative health outcomes and healthcare utilization.
- - Researchers employed latent class analysis on data from large cohorts, including over 1.8 million individuals, to determine how different MLTC clusters impact mortality, hospital hospitalizations, and general practitioner usage over ten years.
- - Findings indicated that certain MLTC clusters, particularly those involving cardiometabolic and pain/mental health issues, showed strong associations with higher risks of mortality and healthcare use, particularly in younger and middle-aged individuals, while data from the UKHLS group did not reveal significant risks.
Background: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from current standard-of-care treatment regimens to BPaL/BPaLM.
Methodology: Country data from national TB programmes (NTP) are used to calculate the costs for all regimens and treatment outcomes.